摘要
目的 检测hMLH1基因的蛋白表达 ,探讨其与卵巢上皮癌生物学行为的关系。方法 应用免疫组化SP法检测 46例卵巢上皮癌中hMLH1基因蛋白的表达。结果 46例卵巢上皮癌中 32例hMLH1蛋白表达阳性 ,占 6 9 6 %。病理学分级 1～ 2级hMLH1表达率明显高于 3级 (P <0 0 5 )。无淋巴结转移组hMLH1表达率高于有淋巴结转移组 (P <0 0 5 )。hMLH1的表达与组织学类型及临床分期无明显的相关性。结论 hMLH1基因可能在卵巢上皮癌的发生、发展过程中起一定的作用 ,且与卵巢上皮癌的恶性程度有关。对其检测将有助于判断卵巢上皮癌的恶性程度及估计预后。
Objective To study the expression of hMLH1 gene in epithelial ovarian cancers and its relationship to clinicopathological feature.Methods The expression of hMLH1 gene in 46 patients with epithelial ovarian cancers were examined by immunohistochemistry SP method.Results hMLH1 expression was observed in 32 of 46 epithelial ovarian cancers(69 6%),and it was significantly higher in FIGO G1～2 than that in G3 tumors(P0 05).Furthermore,the expression rate of hMLH1 was higher in cases with non-lymph node metastasis than those with lymph node metastasis.Analysis also indicated that hMLH1 expression wasn't related to the stages and histological types of the ovarian tumors.Conclusion These results suggest that abnormal expression of hMLH1 be involved in tumorigenic process and the progression of ovarian cancer,and that the loss of the hMLH1 protein expression be a useful predictor for prognosis of ovarian cancer.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2000年第8期497-498,共2页
Chinese Journal of Practical Gynecology and Obstetrics
